SavedAdd your journal

Journals / İstanbul Üniversitesi İstanbul Tıp Fakültesi Mecmuası / 2004 / Cilt: 67 - Sayı: 2

Thymidine labeling index and Ki-67 staining in breast cancer and their relationship to clinical and pathological variables

Bülent AHISHALI
Meral KOYUTURK
Ayhan BİLİR
Ekrem YAVUZ
Pages
92–98
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, TLI and Ki-67 scores may be independent prognostic factors as nuclear grade and hormonal status.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, two proliferation markers; i.e. thymidine labeling index (TLI) and Ki-67 scores of 32 breast cancer patients were evaluated by assessing the relationship with other prognostic parameters including lymph node status, nuclear-histopathologic grades, tumor size, estrogen-progesterone status and menopausal status.
📊
Key Findings & Data:Both TLI values and Kİ67 scores were correlated with nuclear and histologic grades.
💡
Conclusion & Impact:In conclusion, TLI and Ki-67 scores may be independent prognostic factors as nuclear grade and hormonal status.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this study, two proliferation markers; i.e. thymidine labeling index (TLI) and Ki-67 scores of 32 breast cancer patients were evaluated by assessing the relationship with other prognostic parameters including lymph node status, nuclear-histopathologic grades, tumor size, estrogen-progesterone status and menopausal status. Both TLI values and Kİ67 scores were correlated with nuclear and histologic grades. While indices of both proliferation markers were significantly lower in estrogen receptor positive patients than hormone negative patients, only TLI values were found to be significantly lower in progesterone receptor positive patients. No other correlations or associations between variables reached statistical significance. In conclusion, TLI and Ki-67 scores may be independent prognostic factors as nuclear grade and hormonal status.

🔖

Cite This Article

AHISHALI, B., KOYUTURK, M., BİLİR, A., YAVUZ, E. (2022). Thymidine labeling index and Ki-67 staining in breast cancer and their relationship to clinical and pathological variables. İstanbul Üniversitesi İstanbul Tıp Fakültesi Mecmuası, Cilt: 67 - Sayı: 2, 92–98. https://ajindex.com/articles/553665

References (15)

  1. Quinn MC, Wright AN. The clinical assessment of proliferation and growth in human tumours: Evaluation of methods and applications as prognostic variables. J Pathol 1990; 160:93
  2. Scott RJ, Hall A, Haldane JS et al. Comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol 1991; 165:173
  3. Amadori D and Silvestrini R. Prognostic and predictive value of thymidine labelling index in breast cancer. Breast Cancer Res Treat 1998; 51: 267
  4. Burger PC, Shibata T, Kleihues P. The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: Application to surgical neuropathology. Am J Sur Pathol 1986; 10: 611
  5. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990; 17: 489
  6. Midulla C, Cenci M, De Iorio P et al. DNA ploidy and TLI in association with other prognostic parameters in breast cancer. Anticancer Res 1999; 19: 381
  7. Barnard NJ, Hall PA, Lemoine NR, Kadar N. Proliferative index in breast carcinomas determined in-situ by Ki-67 immunostaining and its relationship to clinical and pathological variables. J Pathol 1987; 152: 287
  8. Hasebe T, Mukai K, Tsuda H, Ochiai A. New prognostic histological parameter of invasive ductal carcinoma of the breast: clinicopathological significance of fibrotic focus. Pathol Int 2000; 50: 263
  9. Fisher ER, Redmond C, Fisher B. Histologic grading of breast cancer. Pathol Annu 1980; 15: 239
  10. Black MM, Speer FD, Nuclear structure in cancer tissues. Surg Gynecol Obstet 1957; 105: 97
  11. Daidone MG and Silvestrini R. Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst Monographs 2001; 2001: 27
  12. Del Bino G, Silvestrini R, Costa A, S et al. Morphological and clinical significance of cell kinetics in non-Hodgkin’s lymphomas. Basic Appl Histochem 1986; 30:197
  13. Akerman M, Brandt L, Johnson A, Olsson H. Mitotic activity in non-Hodgkin's lymphoma. Relation to the Kiel classification and to prognosis. Br J Cancer 1987; 55: 219
  14. Ozmen V, Cabioglu N, Dolay K et al. Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome. Breast Cancer Res Treat 2001; 68: 147
  15. Pronzato P, Queirolo P, Vecchio S et al. Thymidine labeling index analysis in early breast cancer patients randomized to receive peri